Patients with advanced gastric cancer who have exhausted multiple lines of treatment often have few options left, particularly those whose tumors are CLDN18.2-positive and HER2-negative. The approval makes it the world's first CAR-T therapy approved for the treatment of solid tumors. CAR-T therapy uses a patient's own immune cells to fight cancer. Like other CAR-T therapies, satricabtagene autoleucel should be administered by experienced medical teams with appropriate supportive care. As more advanced cancer therapies become available, understanding who may benefit is becoming just as important as the treatments themselves.